GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapport Therapeutics Inc (NAS:RAPP) » Definitions » Institutional Ownership

RAPP (Rapport Therapeutics) Institutional Ownership : 77.57% (As of Dec. 11, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Rapport Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Rapport Therapeutics's institutional ownership is 77.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Rapport Therapeutics's Insider Ownership is 6.09%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Rapport Therapeutics's Float Percentage Of Total Shares Outstanding is 91.86%.


Rapport Therapeutics Institutional Ownership Historical Data

The historical data trend for Rapport Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapport Therapeutics Institutional Ownership Chart

Rapport Therapeutics Historical Data

The historical data trend for Rapport Therapeutics can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 25.81 27.33 24.46 34.02 34.07 34.14

Rapport Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Rapport Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
1325 Boylston Street, Suite 401, Boston, MA, USA, 02215
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.